Odanacatib (MK0822)

Description: Odanacatib (also known as MK-0822) is a potent, selective, and neutral inhibitor of cathepsin K (human/rabbit) with the potential to be used for the treatment for osteoporosis and bone metastasis. It inhibits cathepsin K (human/rabbit) with IC50s of 0.2 nM/1 nM, and exhibited high selectivity over off-target cathepsin B, L, S. Odanacatib selectively binds to and inhibits the activity of cathepsin K, which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Currently, Odanacatib is undergoing evaluation for fracture risk reduction in a phase III trial with ?16000 patients with postmenopausal osteoporosis.

References: Bioorg Med Chem Lett. 2008 Feb 1; 18(3):923-8; J Bone Miner Res. 2011 Feb; 26(2):252-62

Chemical Name: (S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-(((S)-2, 2, 2-trifluoro-1-(4'-(methylsulfonyl)-[1, 1'-biphenyl]-4-yl)ethyl)amino)pentanamide

InChi Key: FWIVDMJALNEADT-SFTDATJTSA-N

InChi Code: InChI=1S/C25H27F4N3O3S/c1-23(2, 26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27, 28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3, 34)35/h4-11, 20-21, 31H, 12-14H2, 1-3H3, (H, 32, 33)/t20-, 21-/m0/s1

SMILES Code: CC(C)(F)C[CH](N[CH](C1=CC=C(C2=CC=C(S(=O)(C)=O)C=C2)C=C1)C(F)(F)F)C(NC3(C#N)CC3)=O